Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUPHARMA PLC Board/Management Information 2015

Sep 30, 2015

7703_rns_2015-09-30_de406e61-efeb-4c7f-aa92-a85f0f1260d6.html

Board/Management Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6273A

Immupharma PLC

30 September 2015

FOR IMMEDIATE RELEASE 30 SEPTEMBER 2015

TIM MCCARTHY APPOINTED AS NON-EXECUTIVE CHAIRMAN

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said:

"We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board.  Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy."

Current Directorships

Ark Analytics Solutions Limited

BBN International Limited

Dropped Limited

Expedeon Holdings Limited

Frangipani Dreams Limited

Harvard Healthcare Limited

Incanthera Limited

Spear Therapeutics Limited

Unnamed Limited

Wise Old Owl Limited

Directorships in the Last 5 years

Retail Service Team Limited*

*This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015.

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

For further information please contact:

ImmuPharma plc + 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413 496
Panmure, Gordon & Co., NOMAD & Broker + 44 (0) 20 7886 2500
Fred Walsh, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAPKCDNOBKDNCB